ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07705
0,00%
Bitcoin
61.567,29
0,19%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) News

ARVN

Arvinas (ARVN)

Arvinas Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARVN
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202422h42GlobeNewswire Inc.Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressNASDAQ:ARVNArvinas Inc
07/05/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARVNArvinas Inc
07/05/202413h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
07/05/202413h00GlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
02/05/202413h00GlobeNewswire Inc.Arvinas to Present at Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
24/04/202422h30GlobeNewswire Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNASDAQ:ARVNArvinas Inc
11/04/202413h00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNASDAQ:ARVNArvinas Inc
18/03/202421h40GlobeNewswire Inc.Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerNASDAQ:ARVNArvinas Inc
04/03/202413h00GlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
28/02/202400h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
28/02/202400h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
28/02/202400h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
28/02/202400h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
27/02/202422h46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARVNArvinas Inc
27/02/202413h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
27/02/202413h00GlobeNewswire Inc.Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
20/02/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
20/02/202422h05GlobeNewswire Inc.Arvinas Announces Chief Financial Officer TransitionNASDAQ:ARVNArvinas Inc
20/02/202413h00GlobeNewswire Inc.Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseNASDAQ:ARVNArvinas Inc
14/02/202414h00GlobeNewswire Inc.Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast CancerNASDAQ:ARVNArvinas Inc
14/02/202402h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARVNArvinas Inc
06/02/202412h45GlobeNewswire Inc.Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:ARVNArvinas Inc
01/02/202422h30GlobeNewswire Inc.Arvinas to Present at 6th Annual Guggenheim Biotechnology ConferenceNASDAQ:ARVNArvinas Inc
16/01/202423h01GlobeNewswire Inc.Arvinas Appoints Jared Freedberg as General CounselNASDAQ:ARVNArvinas Inc
16/01/202422h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARVNArvinas Inc
08/01/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
08/01/202413h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
08/12/202315h16Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ARVNArvinas Inc
06/12/202313h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
06/12/202304h52GlobeNewswire Inc.Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development ProgramNASDAQ:ARVNArvinas Inc
 Showing the most relevant articles for your search:NASDAQ:ARVN

Kürzlich von Ihnen besucht

TSXV
CYTO
Cytophage Technologies
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten